What about the side effects and whether any relation to CD4 counts?
CDC Recommends Daily Truvada to Prevent HIV Acquisition in High-Risk Adults — Physician’s First Watch
CDC Recommends Daily Truvada to Prevent HIV Acquisition in High-Risk Adults
By Amy Orciari Herman
The CDC now recommends daily treatment with Truvada to lower the risk for HIV acquisition among high-risk adults, including some men who have sex with men (MSM) and injection drug users. The Truvada pill contains 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine.
Among the groups for whom pre-exposure prophylaxis with Truvada is recommended:
MSM not in a monogamous relationship who engage in unprotected anal intercourse
Heterosexually active adults who rarely use condoms during sex with high-risk partners of unknown HIV status
All adults in an ongoing relationship with an HIV-infected partner
Injection drug users who share needles
Individuals must test negative for HIV before beginning Truvada, and they should be assessed every 3 months thereafter. Those who acquire HIV should discontinue the drug.
HIV/ID expert Paul Sax commented: "It is clear that this intervention prevents HIV infection among those who are compliant with the regimen. The key will be targeting those who are at highest risk, a task that will fall on primary care providers."
Reader Comments (3)
My concern here is the high chances of developing resistant strains.
How come the prophylactic medications are nucleoside and nucleotide reverse transcriptase inhibitors (emtricitabine and tenofovir) and not entry inhibitors (enfuvirtide and maraviroc) or integrase inhibitor (raltegravir)?